Mochi vs Hers: Genetic Testing & GLP-1 Selection

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Mochi and Hers are well-known telehealth platforms that deliver GLP-1 medications directly to patients. Both emphasize convenience and accessibility, but research shows that platform choice alone does not predict individual medication response—biomarkers and genetic predispositions do. Understanding how these two platforms approach assessment, combined with genetic insight, helps clarify what precision GLP-1 care actually involves.

When comparing Mochi vs Hers, many patients focus on app design, shipping speed, or subscription cost. However, clinical outcomes depend more on whether the underlying assessment captures individual variation in peptide pathways. This article explores both platforms, the limitations of convenience-first telehealth, and how genetic testing can support a more informed conversation with your provider about GLP-1 selection.

What Are Mochi and Hers: Platform Models and Service Scope

Mochi is a telehealth platform specializing in GLP-1 and other metabolic medications. It connects users with a network of providers, offers at-home consultations, and ships compounded or branded medications depending on state and prescription. Mochi emphasizes rapid onboarding and flexible dosing protocols.

Hers (formerly Ro Women) is a broader telehealth service offering GLP-1 medications alongside hormone therapy, skincare, and other prescriptions. Hers historically marketed to women but now serves all patients seeking GLP-1. Both platforms prioritize convenience, but neither routinely incorporates genetic testing or detailed biomarker profiling into their standard assessment pathway.

Platform Comparison: Assessment Depth and Customization Framework

Both Mochi and Hers rely on online questionnaires, medical history review, and provider consultation to determine GLP-1 eligibility. However, their depth of metabolic assessment and individualization strategies differ. The table below outlines key distinctions in how each platform approaches patient evaluation and medication selection.

Assessment Factor	Mochi Approach	Hers Approach	Precision-Guided Standard
Genetic Testing	Not typically included	Not typically included	Peptide pathway variants (GIPR, GLP1R, FTO, MC4R)
Baseline Metabolic Biomarkers	Standard medical history only	Standard medical history only	Fasting glucose, insulin, lipid panel when available
Medication Selection Criteria	Provider discretion + patient preference	Provider discretion + patient preference	Genetic predisposition + biomarker context
Follow-up Monitoring	Symptom-based adjustments	Symptom-based adjustments	Periodic biomarker review + response tracking

Clinical Evidence: Why Telehealth Convenience Does Not Guarantee Precision

A 2023 systematic review in Obesity noted that GLP-1 medication response varies widely across individuals, with 15–30% of users experiencing minimal weight loss despite adherence. This variation is partly driven by genetic polymorphisms in GLP-1 receptor (GLP1R) and glucose-dependent insulinotropic peptide receptor (GIPR) pathways. Neither Mochi nor Hers uses this genetic insight in standard practice.

Telehealth platforms like Mochi and Hers excel at reducing barriers to access and speeding initiation. However, without biomarker context or genetic assessment, providers must rely on trial-and-error dosing and medication switching. This approach works for many patients but may delay optimal outcomes for individuals whose genetic profile predicts lower responsiveness to certain agents.

The Role of Genetic Testing in GLP-1 Selection Beyond Telehealth

Precision Peptide Genetic Testing evaluates key variants in GLP-1 signaling pathways—GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—that may influence medication response and side-effect tolerance. This test does not predict exact outcomes, but it can provide context to inform your provider conversation and support more individualized protocol decisions.

PlexusDx offers Precision Peptide Genetic Testing as an add-on ($99) or standalone ($298) service. The results are designed to be interpreted with a qualified healthcare provider to help clarify whether semaglutide, tirzepatide, or other peptide agents may align better with your biological profile. This approach complements—not replaces—telehealth platforms like Mochi or Hers.

Safety, Eligibility, and When to Choose a Precision-Guided Pathway

Both Mochi and Hers screen for contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome, pregnancy, and kidney disease. Standard screening is appropriate and necessary. However, genetic testing can further refine risk stratification and help identify individuals who may be prone to side effects or slow response.

If you are considering GLP-1 therapy through Mochi, Hers, or another platform, ask your provider about baseline metabolic biomarkers and whether genetic insight into peptide pathways might inform your medication choice. This combination—telehealth convenience plus precision assessment—represents a more informed approach to GLP-1 initiation and dose optimization.

How PlexusDx Supports a More Personalized Approach

PlexusDx supports patients seeking GLP-1 medications with access to compounded semaglutide and tirzepatide from licensed 503A pharmacies, paired with optional Precision Peptide Genetic Testing. Genetic insight into GLP1R, GIPR, FTO, and MC4R variants may help provide context for why certain individuals respond differently to the same medication.

The Precision Peptide Genetic Test ($99 add-on or $298 standalone) analyzes predispositions in peptide signaling pathways and should be interpreted with a qualified healthcare provider. Results do not guarantee medication response but can support a more personalized conversation with your clinician about which GLP-1 agent might align with your genetic and metabolic profile.

Whether you choose Mochi, Hers, or another telehealth service, consider asking about biomarker screening and genetic assessment options. PlexusDx patients often combine telehealth convenience with precision genetic testing to inform their GLP-1 selection and protocol adjustment decisions, moving beyond one-size-fits-all approaches.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between Mochi and Hers for GLP-1 delivery?

Mochi specializes in metabolic medications and emphasizes rapid GLP-1 access. Hers offers GLP-1 alongside broader telehealth services (hormone, skincare). Both prioritize convenience; neither routinely includes genetic testing in standard assessment.

Does either Mochi or Hers use genetic testing to choose GLP-1 medications?

No. Both platforms rely on medical history, provider discretion, and patient preference. Genetic testing for peptide pathways is not part of their standard protocols and must be requested separately or through specialized services like PlexusDx.

How does PlexusDx's Precision Peptide Genetic Test fit with Mochi or Hers?

PlexusDx offers genetic testing ($99 add-on or $298 standalone) to evaluate GLP-1 pathway variants. Results can be shared with your Mochi or Hers provider to inform medication selection and personalization—it is a complementary service, not a replacement.

Is compounded semaglutide or tirzepatide from PlexusDx the same as branded Ozempic or Mounjaro?

No. PlexusDx offers compounded formulations from licensed 503A pharmacies. These are not FDA-approved branded medications. Compounded and branded versions differ in manufacturing, regulation, and pricing; discuss options with your healthcare provider.

What does Precision Peptide Genetic Testing actually predict?

The test reveals genetic predispositions in GLP-1 signaling pathways (GLP1R, GIPR, FTO, MC4R). It does not predict exact medication response but may help contextualize why individuals respond differently. Results should be interpreted with a qualified healthcare provider.

Mochi vs Hers: Genetic Testing for GLP-1 Precision